SABSW
Price:
$0.05
Market Cap:
$37.84M
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2021-10-25
Stock Exchange
NASDAQ
Ticker
SABSW
According to SAB Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 33.19M. This represents a change of 129.81% compared to the average of 14.44M of the last 4 quarters.
The mean historical Enterprise Value of SAB Biotherapeutics, Inc. over the last ten years is 971.63M. The current 33.19M Enterprise Value has changed 241.57% with respect to the historical average. Over the past ten years (40 quarters), SABSW's Enterprise Value was at its highest in in the September 2021 quarter at 437.56M. The Enterprise Value was at its lowest in in the December 2023 quarter at -9882010.68.
Average
971.63M
Median
187.06M
Minimum
-12671176.44
Maximum
4.41B
Discovering the peaks and valleys of SAB Biotherapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Enterprise Value = 4.41B
Minimum Annual Increase = -176.53%
Minimum Annual Enterprise Value = -12671176.44
Year | Enterprise Value | Change |
---|---|---|
2023 | -12671176.44 | -176.53% |
2022 | 16.56M | -91.15% |
2021 | 187.06M | -26.13% |
2020 | 253.24M | -94.26% |
The current Enterprise Value of SAB Biotherapeutics, Inc. (SABSW) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
63.65M
5-year avg
971.63M
10-year avg
971.63M
SAB Biotherapeutics, Inc.’s Enterprise Value is less than SAB Biotherapeutics, Inc. (33.19M), less than Jasper Therapeutics, Inc. (235.25M), greater than NRx Pharmaceuticals, Inc. (24.01M), less than Roivant Sciences Ltd. (6.82B), greater than Surrozen, Inc. (10.29M),
Company | Enterprise Value | Market cap |
---|---|---|
33.19M | $37.84M | |
235.25M | $3.45M | |
24.01M | $18.95M | |
6.82B | $8.42B | |
10.29M | $48.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SAB Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like SAB Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is SAB Biotherapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for SAB Biotherapeutics, Inc. (SABSW)?
What is the 3-year average Enterprise Value for SAB Biotherapeutics, Inc. (SABSW)?
What is the 5-year average Enterprise Value for SAB Biotherapeutics, Inc. (SABSW)?
How does the current Enterprise Value for SAB Biotherapeutics, Inc. (SABSW) compare to its historical average?